Related Experiment Video
Updated: Jun 16, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
[Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma]
1Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg i.Br.
Onkologie
|February 19, 2010
Summary
Sunitinib doubles progression-free survival in metastatic renal cell carcinoma (mRCC) first-line therapy. Real-world data from over 4,500 patients confirm its safety and efficacy across diverse patient groups, including those with poor prognoses.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) treatment has advanced with targeted therapies.
- Sunitinib, a multi-kinase inhibitor, is a standard first-line therapy for mRCC.
Purpose of the Study:
- To evaluate the safety and tolerability of Sunitinib in a large, real-world patient population.
- To assess Sunitinib's efficacy in subgroups with unfavorable prognoses.
Main Methods:
- Analysis of data from an expanded access program involving over 4,500 mRCC patients.
- Inclusion of patients ineligible for clinical trials due to exclusion criteria or country-specific restrictions.
- Focus on safety, long-term tolerability, and outcomes in diverse subgroups.
Main Results:
- Sunitinib demonstrated favorable safety and tolerability profiles, consistent with clinical trial data.
- No new or cumulative toxicities were observed in the expanded access program.
- Patients with unfavorable prognoses, including brain metastases or poor performance status, benefited from Sunitinib treatment.
Conclusions:
- Real-world data support Sunitinib's established efficacy and safety in first-line mRCC treatment.
- Sunitinib is effective across a broad spectrum of mRCC patients, including those with challenging prognostic factors.
- The findings reinforce Sunitinib's role as a valuable therapeutic option for mRCC.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...